Browsing by Author "Kantoff, Philip"

Now showing items 1-18 of 18

    • Analysis of the 10q11 Cancer Risk Locus Implicates MSMB and NCOA4 in Human Prostate Tumorigenesis 

      Chanock, Stephen J.; Schafer, Eric J.; Tabernero, Josep; Baselga, José; Oh, William K.; Pomerantz, Mark M; Shrestha, Yashaswi; Flavin, Richard John; Regan, Meredith Margaret; Penney, Kathryn Lee; Mucci, Lorelei Ann; Stampfer, Meir; Hunter, David J.; Chan, Jennifer Ang; Richardson, Andrea Lynn; Loda, Massimo; Kantoff, Philip Wayne; Hahn, William C.; Freedman, Matthew Lawrence (Public Library of Science, 2010)
      Genome-wide association studies (GWAS) have established a variant, rs10993994, on chromosome 10q11 as being associated with prostate cancer risk. Since the variant is located outside of a protein-coding region, the target ...

    • The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis 

      Pomerantz, Mark M.; Li, Fugen; Takeda, David; Lenci, Romina; Chonkar, Apurva; Chabot, Matthew; Cejas, Paloma; Vazquez, Francisca; Cook, Jennifer; Shivdasani, Ramesh A.; Bowden, Michaela; Lis, Rosina; Hahn, William C.; Kantoff, Philip W.; Brown, Myles; Loda, Massimo; Long, Henry W.; Freedman, Matthew L. (2015)
      Master transcription factors interact with DNA to establish cell-type identity and to regulate gene expression in mammalian cells1,2. The genome-wide map of these transcription factor binding sites has been termed the ...

    • ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation 

      Wang, Andrew Z; Yuet, Kai; Zhang, Liangfang; Gu, Frank X; Huynh-Le, Minh; Radovic-Moreno, Aleksandar F; Kantoff, Philip Wayne; Bander, Neil H; Langer, Robert S.; Farokhzad, Omid Cameron (Future Medicine Ltd, 2010)
      Aim: The development of chemoradiation – the concurrent administration of chemotherapy and radiotherapy – has led to significant improvements in local tumor control and survival. However, it is limited by its high toxicity. ...

    • Development of Multinuclear Polymeric Nanoparticles as Robust Protein Nanocarriers 

      Wu, Jun; Kamaly, Nazila; Shi, Jinjun; Zhao, Lili; Xiao, Zeyu; Hollett, Geoffrey; John, Rohit; Ray, Shaunak; Xu, Xiaoyang; Zhang, Xueqing; Kantoff, Philip Wayne; Farokhzad, Omid Cameron (Wiley-Blackwell, 2014)
      One limitation of current biodegradable polymeric nanoparticles is their inability to effectively encapsulate and sustainably release proteins while maintaining protein bioactivity. Here we report the engineering of a ...

    • DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors 

      Bambury, Richard M; Bhatt, Ami S; Riester, Markus; Pedamallu, Chandra Sekhar; Duke, Fujiko; Bellmunt, Joaquim; Stack, Edward C; Werner, Lillian; Park, Rachel; Iyer, Gopa; Loda, Massimo; Kantoff, Philip W; Michor, Franziska; Meyerson, Matthew; Rosenberg, Jonathan E (BioMed Central, 2015)
      Background: To date, there have been no reports characterizing the genome-wide somatic DNA chromosomal copy-number alteration landscape in metastatic urothelial carcinoma. We sought to characterize the DNA copy-number ...

    • Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation 

      Hsieh, Chen-Lin; Fei, Teng; Chen, Yiwen; Li, Tiantian; Gao, Yanfei; Wang, Xiaodong; Sun, Tong; Sweeney, Christopher J; Lee, Gwo-Shu Mary; Chen, Shaoyong; Balk, Steven Paul; Liu, Xiaole (Shirley) Shirley; Brown, Myles Avery; Kantoff, Philip Wayne (Proceedings of the National Academy of Sciences, 2014)
      The androgen receptor (AR) is a key factor that regulates the behavior and fate of prostate cancer cells. The AR-regulated network is activated when AR binds enhancer elements and modulates specific enhancer–promoter ...

    • Functional Enhancers at the Gene-Poor 8q24 Cancer-Linked Locus 

      Landan, Gilad; Jaschek, Rami; Herman, Paula; Yan, Chunli; Khalid, Omar; Oh, William; Manak, J. Robert; Henderson, Brian E.; Frenkel, Baruch; Haiman, Christopher A.; Tanay, Amos; Coetzee, Gerhard A.; Jia, Li; Pomerantz, Mark M; Reich, David Emil; Kantoff, Philip Wayne; Berman, Benjamin P; Freedman, Matthew Lawrence (Public Library of Science, 2009)
      Multiple discrete regions at 8q24 were recently shown to contain alleles that predispose to many cancers including prostate, breast, and colon. These regions are far from any annotated gene and their biological activities ...

    • Identification of ALK Gene Alterations in Urothelial Carcinoma 

      Bellmunt, Joaquim; Selvarajah, Shamini; Rodig, Scott; Salido, Marta; de Muga, Silvia; Costa, Irmgard; Bellosillo, Beatriz; Werner, Lillian; Mullane, Stephanie; Fay, André P.; O'Brien, Robert; Barretina, Jordi; Minoche, André E.; Signoretti, Sabina; Montagut, Clara; Himmelbauer, Heinz; Berman, David M.; Kantoff, Philip; Choueiri, Toni K.; Rosenberg, Jonathan E. (Public Library of Science, 2014)
      Background: Anaplastic lymphoma kinase (ALK) genomic alterations have emerged as a potent predictor of benefit from treatment with ALK inhibitors in several cancers. Currently, there is no information about ALK gene ...

    • Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer 

      Du, Zhou; Sun, Tong; Hacisuleyman, Ezgi; Fei, Teng; Wang, Xiaodong; Brown, Myles; Rinn, John L.; Lee, Mary Gwo-Shu; Chen, Yiwen; Kantoff, Philip W.; Liu, X. Shirley (Nature Publishing Group, 2016)
      Mounting evidence suggests that long noncoding RNAs (lncRNAs) can function as microRNA sponges and compete for microRNA binding to protein-coding transcripts. However, the prevalence, functional significance and targets ...

    • Molecular Sampling of Prostate Cancer: A Dilemma for Predicting Disease Progression 

      Sboner, Andrea; Demichelis, Francesca; Calza, Stefano; Pawitan, Yudi; Hoshida, Yujin; Perner, Sven; Andersson, Swen-Olof; Varenhorst, Eberhard; Johansson, Jan-Erik; Gerstein, Mark B; Rubin, Mark A; Andrén, Ove; Setlur, Sunita Ramakrishna; Adami, Hans-Olov; Fall, Katja; Mucci, Lorelei Ann; Kantoff, Philip Wayne; Stampfer, Meir; Golub, Todd R. (BioMed Central, 2010)
      Background: Current prostate cancer prognostic models are based on pre-treatment prostate specific antigen (PSA) levels, biopsy Gleason score, and clinical staging but in practice are inadequate to accurately predict disease ...

    • Natural History of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer in Men with Favorable Prognostic Indicators 

      Martin, Neil E.; Chen, Ming-Hui; Beard, Clair J.; Nguyen, Paul L.; Loffredo, Marian J.; Renshaw, Andrew A.; Kantoff, Philip W.; D'Amico, Anthony V. (Hindawi Publishing Corporation, 2014)
      Background and Purpose. Life expectancy data could identify men with favorable post-radiation prostate-specific antigen (PSA) failure kinetics unlikely to require androgen deprivation therapy (ADT). Materials and Methods. ...

    • Polycomb-independent activity of EZH2 in castration resistant prostate cancer 

      Xu, Kexin; Wu, Zhenhua; Groner, Anna Claire; He, Housheng H; Cai, Changmeng; Stack, Edward C; Loda, Massimo; Liu, Tao; Morrissey, Colm; Vessella, Robert L; Kantoff, Philip Wayne; Balk, Steven Paul; Liu, Xiaole Shirley; Brown, Myles Avery (BioMed Central, 2013)

    • The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study 

      Kelly, Rachel S.; Sinnott, Jennifer A.; Rider, Jennifer R.; Ebot, Ericka M.; Gerke, Travis; Bowden, Michaela; Pettersson, Andreas; Loda, Massimo; Sesso, Howard D.; Kantoff, Philip W.; Martin, Neil E.; Giovannucci, Edward L.; Tyekucheva, Svitlana; Heiden, Matthew Vander; Mucci, Lorelei A. (BioMed Central, 2016)
      Background: Understanding the biologic mechanisms underlying the development of lethal prostate cancer is critical for improved therapeutic and prevention strategies. In this study we explored the role of tumor metabolism ...

    • Sipuleucel-T Immune Parameters Correlate with Survival: an Analysis of the Randomized Phase 3 Clinical Trials in Men with Castration-Resistant Prostate Cancer 

      Sheikh, Nadeem; Petrylak, Daniel; Kantoff, Philip Wayne; dela Rosa, Corazon; Stewart, Frances P.; Kuan, Ling-Yu; Whitmore, James B.; Trager, James B.; Poehlein, Christian H.; Frohlich, Mark W.; Urdal, David L. (Springer Verlag, 2013)
      Purpose: Sipuleucel-T, the first FDA-approved autologous cellular immunotherapy for treatment of advanced prostate cancer, is manufactured by activating peripheral blood mononuclear cells, including antigen presenting cells ...

    • Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy 

      Wang, Andrew Z.; Bagalkot, Vaishali; Vasilliou, Christophoros C.; Gu, Frank; Alexis, Frank; Zhang, Liangfang; Shaikh, Mariam; Yuet, Kai; Cima, Michael J.; Langer, Robert S.; Kantoff, Philip Wayne; Bander, Neil H.; Jon, Sangyong; Farokhzad, Omid Cameron (Wiley-Blackwell, 2008)

    • Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles 

      Valencia, Pedro M; Pridgen, Eric M; Perea, Brian; Gadde, Suresh; Sweeney, Christopher; Kantoff, Philip Wayne; Bander, Neil H; Lippard, Stephen J; Langer, Robert S.; Karnik, Rohit; Farokhzad, Omid Cameron (Future Medicine Ltd, 2013)
      Aim: Two unexplored aspects for irinotecan and cisplatin (I&C) combination chemotherapy are (1) actively targeting both drugs to a specific diseased cell type and (2) delivering both drugs on the same vehicle to ensure ...

    • Whole exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer 

      Lohr, Jens G.; Adalsteinsson, Viktor A.; Cibulskis, Kristian; Choudhury, Atish D.; Rosenberg, Mara; Cruz-Gordillo, Peter; Francis, Joshua; Zhang, Cheng-Zhong; Shalek, Alex K.; Satija, Rahul; Trombetta, John T.; Lu, Diana; Tallapragada, Naren; Tahirova, Narmin; Kim, Sora; Blumenstiel, Brendan; Sougnez, Carrie; Lowe, Alarice; Wong, Bang; Auclair, Daniel; Van Allen, Eliezer M.; Nakabayashi, Mari; Lis, Rosina T.; Lee, Gwo-Shu M.; Li, Tiantian; Chabot, Matthew S.; Ly, Amy; Taplin, Mary-Ellen; Clancy, Thomas E.; Loda, Massimo; Regev, Aviv; Meyerson, Matthew; Hahn, William C.; Kantoff, Philip W.; Golub, Todd R.; Getz, Gad; Boehm, Jesse S.; Love, J. Christopher (2014)
      Comprehensive analyses of cancer genomes promise to inform prognoses and precise cancer treatments. A major barrier, however, is inaccessibility of metastatic tissue. A potential solution is to characterize circulating ...

    • Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine 

      Allen, Eliezer M. Van; Wagle, Nikhil; Stojanov, Petar; Perrin, Danielle L.; Cibulskis, Kristian; Marlow, Sara; Jane-Valbuena, Judit; Friedrich, Dennis C.; Kryukov, Gregory; Carter, Scott L.; McKenna, Aaron; Sivachenko, Andrey; Rosenberg, Mara; Kiezun, Adam; Voet, Douglas; Lawrence, Michael; Lichtenstein, Lee T.; Gentry, Jeff G.; Huang, Franklin W.; Fostel, Jennifer; Farlow, Deborah; Barbie, David; Gandhi, Leena; Lander, Eric S.; Gray, Stacy W.; Joffe, Steven; Janne, Pasi; Garber, Judy; MacConaill, Laura; Lindeman, Neal; Rollins, Barrett; Kantoff, Philip; Fisher, Sheila A.; Gabriel, Stacey; Getz, Gad; Garraway, Levi A. (2013)
      Translating whole exome sequencing (WES) for prospective clinical use may impact the care of cancer patients; however, multiple innovations are necessary for clinical implementation. These include: (1) rapid and robust WES ...